Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 9,520 matching trials from the live ClinicalTrials.gov search.
Filters: Birmingham, Alabama Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Increasing the Accessibility of a Falls Prevention Intervention for Community Dwelling Older Adults With Low Vision

NCT03028493
View directory record Official record
Conditions
Low Vision, Fall
Interventions
Original SAFE Intervention, Adapted SAFE Intervention
Behavioral
Lead sponsor
Sarah Blaylock
Other
Eligibility
60 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Oct 23, 2026, 10:50 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

NCT03448692
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis (FSGS)
Interventions
PF-06730512
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
56
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 23, 2026, 10:50 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder

NCT02672111
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
CAM2038 q1w or q4w exposure to SL BPN/NX, CAM2038 q1w or q4w new to BPN treatment
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 7 more
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 23, 2026, 10:50 AM EDT
Withdrawn Phase 2 Interventional

huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas

NCT00620607
View directory record Official record
Conditions
Stomach Neoplasms, Metastatic or Locally Advanced Gastric Cancer, Metastatic or Local Advanced GE Junction Cancer
Interventions
huC242-DM4
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Birmingham, Alabama • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 23, 2026, 10:50 AM EDT
Recruiting Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

NCT07228364
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
AZD1613 - Part A, Placebo - Part A, AZD1613 - Part B, Placebo - Part B
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Birmingham, Alabama • Loma Linda, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 10:50 AM EDT
Active, not recruiting Not applicable Interventional

DCM Precision Medicine Study

NCT03037632
View directory record Official record
Conditions
Idiopathic Dilated Cardiomyopathy
Interventions
Family Heart Talk Booklet
Behavioral
Lead sponsor
Ray Hershberger
Other
Eligibility
Not listed
Enrollment
6,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 23, 2026, 10:50 AM EDT
Completed Phase 2 Interventional

Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty

NCT00818493
View directory record Official record
Conditions
Postoperative Pain
Interventions
Q8003 (morphine sulfate and oxycodone hydrochloride), Low dose Q8003 (morphine sulfate and oxycodone hydrochloride), Percocet (oxycodone and acetaminophen)
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Birmingham, Alabama • Phoenix, Arizona • Royal Oak, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Oct 23, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Results available

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

NCT04922021
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
LEO 138559, LEO 138559 placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 64 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 23, 2026, 10:50 AM EDT
Completed Phase 4 Interventional Results available

A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects

NCT01255761
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol (CZP)
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
110
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 23, 2026, 10:50 AM EDT
Not yet recruiting No phase listed Observational

Occlutech AFR Fontan Study

NCT07532369
View directory record Official record
Conditions
Failure of Fontan Type Circulation, Fenestration, Univentricular Heart, Congenital Anomaly
Interventions
Occlutech Atrial Flow Regulator Retrospective Data Collection
Device
Lead sponsor
Occlutech International AB
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 23, 2026, 10:50 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00936741
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • Escondido, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 23, 2026, 10:50 AM EDT
Completed Phase 1 Interventional

A Study of ALS-008176 in Infants Hospitalized With RSV

NCT02202356
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALS-008176, Placebo
Drug
Lead sponsor
Alios Biopharma Inc.
Industry
Eligibility
Up to 12 Months
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 23, 2026, 10:50 AM EDT
Terminated Phase 3 Interventional Results available

Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

NCT02587351
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Metoprolol succinate, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 84 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
27
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 23, 2026, 10:50 AM EDT
Completed Phase 4 Interventional Results available

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain

NCT04442737
View directory record Official record
Conditions
HIV-1
Interventions
D/C/F/TAF FDC, TAF/FTC FDC, INI Based Regimen
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
34
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 23, 2026, 10:50 AM EDT
Terminated Phase 2 Interventional Results available

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

NCT00326872
View directory record Official record
Conditions
Neurofibromatosis Type 1, Plexiform Neurofibroma, Spinal Cord Neurofibroma
Interventions
Cediranib Maleate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
9
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 23, 2026, 10:50 AM EDT
Completed No phase listed Observational

Precision Event Monitoring for Patients With Heart Failure Using HeartLogic

NCT03579641
View directory record Official record
Conditions
Heart Failure, Defibrillators, Implantable, Monitoring, Physiologic, Cardiac Resynchronization Therapy, Cardiovascular Disease, Heart Disease
Interventions
HeartLogic Sensors
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
56
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 23, 2026, 10:50 AM EDT
Recruiting Not applicable Interventional

Early Time-Restricted Eating in Older Adults With Hypertension

NCT07135505
View directory record Official record
Conditions
Hypertension, Eating Behaviors
Interventions
Early time-restricted eating
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 23, 2026, 10:50 AM EDT
Recruiting No phase listed Observational

Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease

NCT06385886
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Linkage Coordinator
Behavioral
Lead sponsor
RTI International
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oakland, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 23, 2026, 10:50 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening

NCT06120205
View directory record Official record
Conditions
Hpv, HPV 16 Infection, HPV Infection, High Risk HPV
Interventions
Teal Wand Self-Collection Device Group
Device
Lead sponsor
Teal Health, Inc.
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
870 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 23, 2026, 10:50 AM EDT
Completed Phase 1 Interventional

A Safety Study of SGN-CD33A in AML Patients

NCT01902329
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia
Interventions
HMA, SGN-CD33A
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
14
States / cities
Birmingham, Alabama • Duarte, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 23, 2026, 10:50 AM EDT
Completed No phase listed Observational

Study of Blood Samples From Newborns With Down Syndrome

NCT00959283
View directory record Official record
Conditions
Myeloid Proliferations Associated With Down Syndrome
Interventions
Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 90 Days
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
173
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 130 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 23, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Results available

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

NCT00818454
View directory record Official record
Conditions
Asthma
Interventions
Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Palmdale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 23, 2026, 10:50 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines

NCT06218251
View directory record Official record
Conditions
Upper Facial Lines
Interventions
BOTOX
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Vista, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 23, 2026, 10:50 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01072929
View directory record Official record
Conditions
Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • Beverly Hills, California • Garden Grove, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 23, 2026, 10:50 AM EDT